Changes in Staging and Management of Non-Small Cell Lung Cancer (NSCLC) Patients Following the Implementation of Low-Dose Chest Computed Tomography (LDCT) Screening at Kaohsiung Medical University Hospital

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Nov 27

PMID 39594683

Authors

Chin-Ling Chen

Jui-Sheng Hsu

Yi-Wen Shen

Chih-Hsiang Hsu

Shih-Yu Kao

Wei-An Lai

Cheng-Hao Chuang

Yu-Wei Liu

Jui-Ying Lee

Shah-Hwa Chou

Jen-Yu Hung

Inn-Wen Chong

Chih-Jen Yang

Affiliations

Soon will be listed here.

Abstract

Background: Low-dose computed tomography (LDCT) has been widely adopted for lung cancer screening due to its proven ability to reduce lung cancer mortality, especially among high-risk populations.

Methods: This retrospective study aims to evaluate the impact of LDCT screening on non-small cell lung cancer (NSCLC) staging at Kaohsiung Medical University Hospital (KMUH) from 2011 to 2020, following the introduction of LDCT in 2013. The study examines the correlation between LDCT screening volume and changes in the distribution of NSCLC stages, particularly early-stage (stages 0 and I) and late-stage (stage IV) diagnoses. Additionally, it explores the differences in histopathological subtypes, focusing on adenocarcinoma and squamous cell carcinoma, and assesses the impact of early detection on five-year survival rates.

Results: The results show a significant increase in early-stage NSCLC diagnoses, particularly in adenocarcinoma cases, where early-stage diagnoses rose from 10.4% in 2010 to 38.7% in 2019. However, the number of stage IV cases remained stable, indicating that LDCT may not substantially reduce late-stage diagnoses. Pearson's correlation analysis demonstrated a strong positive correlation between LDCT screening and early-stage NSCLC detection, particularly for adenocarcinoma ( < 0.001), though the early detection of squamous cell carcinoma and small cell carcinoma remained limited.

Conclusions: The study concludes that LDCT screening plays a crucial role in improving early NSCLC detection and five-year survival rates. Future research should focus on optimizing screening strategies to capture more at-risk populations and enhance the detection of harder-to-diagnose subtypes like squamous cell carcinoma.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Black W, Keeler E, Soneji S . Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015; 372(4):388. DOI: 10.1056/NEJMc1414726. View

Tseng C, Tsuang B, Chiang C, Ku K, Tseng J, Yang T . The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan. J Thorac Oncol. 2019; 14(5):784-792. DOI: 10.1016/j.jtho.2018.12.033. View

Fischer B, Mortensen J, Hojgaard L . Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2002; 2(11):659-66. DOI: 10.1016/S1470-2045(01)00555-1. View

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel C . European position statement on lung cancer screening. Lancet Oncol. 2017; 18(12):e754-e766. DOI: 10.1016/S1470-2045(17)30861-6. View

Krist A, Davidson K, Mangione C, Barry M, Cabana M, Caughey A . Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325(10):962-970. DOI: 10.1001/jama.2021.1117. View

Du Y, Li Y, Dorrius M, Sidorenkov G, Vonder M, Vliegenthart R . Comparison of National Comprehensive Cancer Network and European Position Statement protocols for nodule management in low-dose computed tomography lung cancer screening in a general Chinese population. J Thorac Dis. 2022; 13(12):6855-6865. PMC: 8743405. DOI: 10.21037/jtd-21-1312. View

Vansteenkiste J, Stroobants S . PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol. 2007; 1(1):71-3. View

Printz C . US Preventive Services Task Force issues new draft recommendation statement regarding lung cancer screening. Cancer. 2020; 126(19):4269. DOI: 10.1002/cncr.33193. View

10.

Field J, Aberle D, Altorki N, Baldwin D, Dresler C, Duffy S . The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014; 9(2):141-3. DOI: 10.1097/JTO.0000000000000060. View

11.

Wu F, Huang Y, Wu C, Tang E, Chen C, Mar G . Assessment of Selection Criteria for Low-Dose Lung Screening CT Among Asian Ethnic Groups in Taiwan: From Mass Screening to Specific Risk-Based Screening for Non-Smoker Lung Cancer. Clin Lung Cancer. 2016; 17(5):e45-e56. DOI: 10.1016/j.cllc.2016.03.004. View

12.

Yang C, Lin Y, Lin L, Chang Y, Chen H, Wang Y . Stage Shift Improves Lung Cancer Survival: Real-World Evidence. J Thorac Oncol. 2023; 18(1):47-56. DOI: 10.1016/j.jtho.2022.09.005. View

13.

Vansteenkiste J, Stroobants S . The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J. 2001; 17(4):802-20. DOI: 10.1183/09031936.01.17408020. View

14.

Tsai S, Chiu Y, Weng Y, Yang C . Association between fine particulate air pollution and the risk of death from lung cancer in Taiwan. J Toxicol Environ Health A. 2022; 85(10):431-438. DOI: 10.1080/15287394.2022.2040672. View

15.

Thun M, Henley S, Burns D, Jemal A, Shanks T, Calle E . Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006; 98(10):691-9. DOI: 10.1093/jnci/djj187. View

16.

Fischer B, Mortensen J . The future in diagnosis and staging of lung cancer: positron emission tomography. Respiration. 2006; 73(3):267-76. DOI: 10.1159/000092080. View

17.

Lam D, Liam C, Andarini S, Park S, Tan D, Singh N . Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023; 18(10):1303-1322. DOI: 10.1016/j.jtho.2023.06.014. View

18.

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

19.

Ganti A, Klein A, Cotarla I, Seal B, Chou E . Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021; 7(12):1824-1832. PMC: 8532041. DOI: 10.1001/jamaoncol.2021.4932. View

20.

Tsai S, Chen C, Yang C . The impacts of reduction in ambient fine particulate (PM) air pollution on life expectancy in Taiwan. J Toxicol Environ Health A. 2022; 85(22):913-920. DOI: 10.1080/15287394.2022.2110343. View